Noninvasive Estimation of Normalized Distribution Volume: Application to the Muscarinic-2 Ligand [(18)F]FP-TZTP
Overview
Endocrinology
Neurology
Affiliations
Reference tissue methods to estimate neuroreceptor binding are not applicable to [(18)F]FP-TZTP (a muscarinic-2 cholinergic receptor ligand), because there is no suitable receptor-free reference region. We evaluated a new method to estimate, without using arterial data or a receptor-free reference region, a receptor parameter called the normalized distribution volume, V(T)(*), using a region containing receptors as the input tissue. V(T)(*) is defined as V(T)/K'(1) (distribution volume (V(T)) normalized by K'(1) of the input region). We used a two-parameter multilinear reference tissue model (MRTM2) to generate parametric images of V(T)(*) and R(1) (R(1)=K(1)/K'(1)) from [(18)F]FP-TZTP PET data of healthy aged subjects (10 with apolipoprotein E-epsilon4 alleles (APOE-epsilon4(+)) and nine without (APOE-epsilon4(-)). V(T)(*) and V(T) were normalized by plasma-free fraction, f(P). By one-tissue kinetic analysis (1TKA) with metabolite-corrected plasma data, V(T) was previously reported as higher in the APOE-epsilon4(+) group. The noise magnitude of MRTM2 V(T)(*) and R(1) images were nearly identical to those of 1TKA V(T) and K(1) images. K'(1) or f(P) was not different between the two groups. V(T)(*) (mins) (1,659+/-497) and V(T) (mL/cm(3)) (701+/-99) in APOE-epsilon4(+) were higher by 38 and 22% than those (1,209+/-233 and 577+/-112) in APOE-epsilon4(-), respectively. The statistical significance for V(T)(*) (0.041) was lower than that for V(T) (0.025), due to the higher intersubject variability of V(T)(*) (25%) than that of V(T) (17%). We conclude that MRTM2 V(T)(*) allows detection of group differences in receptor binding without arterial blood or a receptor-free reference region.
Quantitative parametric maps of O-(2-[F]fluoroethyl)-L-tyrosine kinetics in diffuse glioma.
Koopman T, Verburg N, Pouwels P, Wesseling P, Hoekstra O, de Witt Hamer P J Cereb Blood Flow Metab. 2019; 40(4):895-903.
PMID: 31122112 PMC: 7074601. DOI: 10.1177/0271678X19851878.
Ballard M, Dean A, Mandelkern M, London E PLoS One. 2015; 10(12):e0143510.
PMID: 26657223 PMC: 4699455. DOI: 10.1371/journal.pone.0143510.
Chen Y, Rosario B, Mowrey W, Laymon C, Lu X, Lopez O J Nucl Med. 2015; 56(8):1199-205.
PMID: 26045309 PMC: 4730871. DOI: 10.2967/jnumed.114.152405.
Ballard M, Mandelkern M, Monterosso J, Hsu E, Robertson C, Ishibashi K Int J Neuropsychopharmacol. 2015; 18(7):pyu119.
PMID: 25603861 PMC: 4540098. DOI: 10.1093/ijnp/pyu119.
Brust P, van den Hoff J, Steinbach J Neurosci Bull. 2014; 30(5):777-811.
PMID: 25172118 PMC: 5562586. DOI: 10.1007/s12264-014-1460-6.